Eli Lilly and Novo Nordisk are seeking to test some of their most popular drugs approved for Type 2 diabetes and weight management in adults on children.
Drugmakers Eli Lilly and Novo Nordisk are testing some of their most popular diabetes and weight loss drugs on patients as young as 6. Indiana-based Lilly is planning to test tirzepatide, sold under the brand name Mounjaro, on children and teenagers with Type 2 diabetes who are overweight or clinically obese, according to the drugmaker's website.
" The drug is seen as a potential game changer in the treatment of obesity after it helped people with diabetes who were overweight or obese lose up to 15.7% of their body weight. It is expected to be approved by federal health officials for weight loss by the end of the year.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly to Test Mounjaro on Kids as Young as 6Eli Lilly is planning a clinical trial of its diabetes drug Mounjaro in patients six years and older who have obesity, Bloomberg News reported Friday, citing a person familiar with the matter.
Read more »
Eli Lilly targets firms that import and sell imitation Mounjaro onlineEli Lilly filed a complaint with the U.S. International Trade Commission to block companies from importing and selling cheaper versions of its hit drug Mounjaro.
Read more »
GE HealthCare teams up with Novo Nordisk to treat diabetes without drugsNew ultrasound technology has potential to regulate metabolic function, early-stage clinical research shows
Read more »
Sanofi to offer insulin product for $35 to all Americans through GoodRxThe effort comes after Sanofi, Eli Lilly and Novo Nordisk announced sweeping insulin price cuts earlier this year.
Read more »
Sanofi to offer insulin product for $35 to all Americans through GoodRxThe effort comes after Sanofi, Eli Lilly and Novo Nordisk announced sweeping insulin price cuts earlier this year.
Read more »
2 Stocks Set to Capitalize on the Surging Weight Loss Drug TrendStocks Analysis by The Tokenist (Timothy Fries) covering: Eli Lilly and Company, Novo Nordisk A/S. Read The Tokenist (Timothy Fries)'s latest article on Investing.com
Read more »